Evidence map›Paper›PMID 42098817›Full record

ReviewJournal of translational medicine2026

Cross-reactive tissue-resident memory T lymphocytes-concepts, evidence, and open questions.

Hong Lei, Ying Sun, Weihua Gong, Jun Dong

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hong LeiKey Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, Shaanxi Institute for Pediatric Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, 710003, China. leihongnk@163.com.ORCID 0000-0002-6242-0129
Ying SunKey Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, Shaanxi Institute for Pediatric Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, 710003, China.
Weihua GongDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Jun DongCell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), An Institute of the Leibniz Association, Berlin, Germany. dong@drfz.de.ORCID 0000-0001-5218-7979

Funding

Deutsche Forschungsgemeinschaft 389687267Leibniz-Gemeinschaft K470/2022Ministry of Science and Technology of the People's Republic of China DL2023041009LNational Natural Science Foundation of China 82200728
6 · The paper itself

Abstract

backgroundTissue-resident memory T (Trm) cells have emerged as a distinct lymphocyte lineage that provides rapid, frontline immune surveillance in peripheral tissues while also contributing to durable systemic immunity. A critical and evolving aspect of Trm cell biology is their inherent cross-reactivity-the ability of a single T cell receptor (TCR) to recognize and respond to multiple related or unrelated antigens beyond its primary target. MAIN BODY: This review synthesizes current knowledge on the dual roles of cross-reactive Trm cells, which can mediate broad protection against heterologous infections and cancers but may also precipitate or exacerbate autoimmune pathology. We first address the developmental origins, tissue-specific distribution (from barrier surfaces to internal organs, including the central nervous system and bone marrow niches), and key functions that define the Trm population. A central focus is placed on the mechanistic basis of TCR cross-reactivity, comparing and contrasting its regulation in circulating memory T cells versus Trm cells. We delve into how tissue-specific signals, particularly local cytokine milieus and epigenetic reprogramming such as demethylation imprints, shape the functional avidity and antigenic breadth of Trm cell responses. Finally, we discuss emerging therapeutic strategies designed to either harness the protective cross-reactivity of Trm cells for next-generation vaccines and immunotherapies or to restrain its detrimental potential in autoimmune and inflammatory diseases.

conclusionsTrm cells are powerful immune sentinels whose TCR cross-reactivity enables broad protection but also risks autoimmunity. Understanding these precise rules is key to developing Trm-based immunotherapies against cancer and infections while avoiding autoimmunity.

Indexed as

Immunologic MemoryMemory T CellsOrgan SpecificityAnimalsCross ReactionsHumansReceptors, Antigen, T-CellReceptors, Antigen, T-CellAutoimmunityCancerCross-reactivityDemethylationTissue-resident memory T cells

Identifiers

PMID42098817
PMCPMC13159280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.